

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT4870305

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
OTTAWA HOSPITAL RESEARCH INSTITUTE	03/29/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	TURNSTONE LIMITED PARTNERSHIP
<b>Street Address:</b>	1 FIRST CANADIAN PLACE
<b>City:</b>	TORONTO
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	M5X 1B8
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15919554
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(778)329-0752
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	ipmailvancouver@blg.com
<b>Correspondent Name:</b>	BORDEN LADNER GERVAIS LLP
<b>Address Line 1:</b>	1200 WATERFRONT CENTRE, 200 BARRARD STR.
<b>Address Line 4:</b>	VANCOUVER, CANADA V7X 1T2
<b>ATTORNEY DOCKET NUMBER:</b>	PAT 7522AW-2
<b>NAME OF SUBMITTER:</b>	ERIN STEFFEN
<b>SIGNATURE:</b>	/Erin Steffen/
<b>DATE SIGNED:</b>	03/16/2018
<b>Total Attachments: 14</b>	
source=PAT_7522AW-2_-_Confirmatory_Assignment_from_OHRI_to_TLPUS#page1.tif	
source=PAT_7522AW-2_-_Confirmatory_Assignment_from_OHRI_to_TLPUS#page2.tif	
source=PAT_7522AW-2_-_Confirmatory_Assignment_from_OHRI_to_TLPUS#page3.tif	
source=PAT_7522AW-2_-_Confirmatory_Assignment_from_OHRI_to_TLPUS#page4.tif	
source=PAT_7522AW-2_-_Confirmatory_Assignment_from_OHRI_to_TLPUS#page5.tif	
source=PAT_7522AW-2_-_Confirmatory_Assignment_from_OHRI_to_TLPUS#page6.tif	
source=PAT_7522AW-2_-_Confirmatory_Assignment_from_OHRI_to_TLPUS#page7.tif	

source=PAT\_7522AW-2\_-\_Confirmatory\_Assignment\_from\_OHRI\_to\_TLPUS#page8.tif  
source=PAT\_7522AW-2\_-\_Confirmatory\_Assignment\_from\_OHRI\_to\_TLPUS#page9.tif  
source=PAT\_7522AW-2\_-\_Confirmatory\_Assignment\_from\_OHRI\_to\_TLPUS#page10.tif  
source=PAT\_7522AW-2\_-\_Confirmatory\_Assignment\_from\_OHRI\_to\_TLPUS#page11.tif  
source=PAT\_7522AW-2\_-\_Confirmatory\_Assignment\_from\_OHRI\_to\_TLPUS#page12.tif  
source=PAT\_7522AW-2\_-\_Confirmatory\_Assignment\_from\_OHRI\_to\_TLPUS#page13.tif  
source=PAT\_7522AW-2\_-\_Confirmatory\_Assignment\_from\_OHRI\_to\_TLPUS#page14.tif

## CONFIRMATORY ASSIGNMENT

**THIS CONFIRMATORY ASSIGNMENT** is hereby executed for the purpose of recording the assignment in various patent offices. This confirmatory assignment is between **Turnstone Limited Partnership**, by Turnstone (GP) Ontario Inc., in its capacity as the general partner of Turnstone Limited Partnership, having an address at 1 First Canadian Place, Toronto, Ontario, M5X 1B8 ("**TLP**") and **Ottawa Hospital Research Institute**, having an address at 501 Smyth Road, Ottawa, Ontario, K1H 8L6 (the "**Institute**"). TLP and the Institute, are collectively referred to as the "Parties" and individually as a "Party".

### RECITALS:

A. The Parties entered into that certain agreement titled Assignment and Termination Agreement dated 2nd of October, 2015 (the "**Assignment and Termination Agreement**").

B. Under the Assignment and Termination Agreement, the Institute assigned, transferred and conveyed, to TLP, effective as of October 2, 2015 (the "**Effective Date**"), any and all of their right, title and interest in the Assigned Technology (as defined in the Assignment and Termination Agreement).

C. This assignment is intended to confirm the assignment, transfer and conveyance to TLP of the Assigned Technology and the patents relating thereto effective as of the Effective Date.

### 1. Definitions

Capitalized terms in this Assignment have the meanings given to such terms in the Assignment and Termination Agreement.

### 2. Assignment

For and in consideration of the sum of One Hundred Canadian Dollars (CA\$100), and other good and valuable consideration, the receipt of which is acknowledged by the Institute, the Institute hereby confirms that it has assigned, transferred and conveyed to TLP, effective as of the Effective Date, any and all of its right, title and interest in the Assigned Technology including the Patents listed in Schedule 1 to this confirmatory assignment. The Institute confirms having assigned, transferred and conveyed, to TLP their full and exclusive right, title and interest in and to the inventions described and claimed in such Patents worldwide, patents and patent applications for the inventions, all continuations, continuations in part, divisions, re-issues, re-examinations or extensions of the foregoing, foreign patent applications and patents corresponding to any of the foregoing and any patent, patent applications, continuations, continuations-in-part, divisions, re-issues, re-examinations or extensions for improvements to the foregoing.

The Institute consents to the assignment of the share of rights in the Assigned Technology owned by co-applicant(s), McMaster University and/or Children's Hospital of Eastern Ontario Research Institute Inc., to Turnstone Limited Partnership.

### 3. Other Rights

The assignment, transfer and conveyance of Assigned Technology hereunder includes the right to bring a Claim, litigation or other proceeding, at law or in equity or otherwise, for any past, present and/or future infringement, breach, interference, violation, dilution, depreciation or misappropriation such Assigned Technology and to receive all monies, income, royalties, damages, compensation and other relief in connection with such Assigned Technology.

### 4. Further Assurances

The Institute agrees, with reasonable diligence, to do all such things and provide all such reasonable assurances as may be required to consummate the transactions contemplated by this Assignment, and the Institute shall provide such further documents or instruments required by TLP as may be reasonably necessary to effect the purpose of this Assignment and carry out its provisions, whether before or after the Effective Date.

### 5. Miscellaneous Provisions

(a) Applicable Law. This Assignment shall be governed by, and construed in accordance with, the laws of the Province of Ontario and the Federal laws of Canada applicable in the Province of Ontario (without giving effect to the choice of law principles thereof), and the Parties agree to attorn to the Courts of the Province of Ontario sitting in the City of Toronto to resolve any disputes that may arise under this Assignment and irrevocably waive, to the fullest extent it may effectively do so, the defence of an inconvenient forum to the maintenance of such action, application or proceeding.

(b) Headings. The paragraph headings contained in this Assignment are for convenient reference only and shall not affect the meaning or interpretation hereof.

(c) Successors and Assigns. This Assignment shall enure to the benefit of and is binding upon the Parties and their respective successors and permitted assigns.

(d) Counterpart Execution. This Assignment may be executed in separate counterparts and may be executed and delivered by facsimile and all such executed counterparts and facsimiles together shall constitute one agreement.

(e) The undersigned hereby authorize the firm of **Borden Ladner Gervais LLP** to correct errors in this assignment or to insert any further identification or other information necessary or desirable to make this Confirmatory Assignment suitable for recordal throughout the world.

**IN WITNESS WHEREOF**, the Parties hereto have caused this Assignment to be duly executed by their respective authorized officers.

[Remainder of this page intentionally left blank]


**OTTAWA HOSPITAL RESEARCH INSTITUTE**

Executed at Ottawa  
City  
Ontario, Canada  
Province/State, Country

This 29 day of March, 2017.  
Day Month

By: Marisa Akow  
**Director, Research Administration**

Title: \_\_\_\_\_

  
Signature

**Witness:**


I, Anouk Fortin  
Print Name

whose full post office address

is: 1269 Greyrock cr.  
Ottawa, Ontario K2C 2A6 Canada

was personally present and did see  
Marisa Akow  
Print Name

execute the within assignment and such representative is personally known to me.

  
Signature

**TURNSTONE (GP) ONTARIO INC., in its capacity as general partner of TURNSTONE LIMITED PARTNERSHIP**

Herewith declare that they accept the assignment executed at Ottawa  
City  
Ontario, Canada  
Province/State, Country

This 28<sup>th</sup> day of July, 2017.  
Day Month

By: Maura Campbell  
Print Name

Title: Secretary

  
Signature

**Witness:**


I, JOYCE WILSON  
Print Name

whose full post office address

is: 100 VARLEY LANE, APT 105  
OTTAWA, ON K2K 1E5

was personally present and did see  
MAURA CAMPBELL  
Print Name

execute the within assignment and such representative is personally known to me.

  
Signature

**Schedule 1 to Confirmatory Assignment**

<b>Patent Family: TBI-001</b>					
<b>Inventors:</b> David Stojdl, Christopher Brown and John Bell			<b>Owner:</b> Ottawa Hospital Research Institute		
<b>Patent Family:</b> Oncolytic Rhabdovirus  ( <b>Abstract</b> – Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties <i>in vitro</i> and <i>in vivo</i> )				<b>Priority Date:</b> September 15, 2006. (US 60/844,726)	
<b>Country</b>	<b>Number</b>	<b>Associate</b>	<b>Filing Date</b> dd/mm/yr	<b>Reference No.</b>	<b>Status or Patent No.</b>
PCT	PCT/IB2007/004701 WO 09/016433 (published 05/02/09)  Originally identified as PCT/US2007/078673	Morgan Lewis	17/09/07	<b>TBI-001PC</b>	National Phase In: Canada, China, Europe, Japan and US
Canada	2,663,034	Gowlings	17/09/07	<b>TBI-001CA</b>	Issued 2,663,034
China	200780040733.6	CCPIT Patent & Trademark Law Office	17/09/07	<b>TBI-001CN</b>	Issued 200780040733.6
Europe	2007875168	Dehmel & Bettenhausen Patentanwälte	17/09/07	<b>TBI-001EP</b>	Issued EP 2064229
Austria	Validation of EP patent	Sonn & Partner	17/09/07	<b>TBI-001AT</b>	Issued E741511
Belgium	Validation of EP patent	De Clercq & Partners CVBA	17/09/07	<b>TBI-001BE</b>	Issued EP 2064229
France	Validation of EP patent	Dehmel & Bettenhausen Patentanwälte	17/09/07	<b>TBI-001FR</b>	Issued EP 2064229
Germany	Validation of EP patent	Dehmel & Bettenhausen Patentanwälte	17/09/07	<b>TBI-001DE</b>	Issued 602007042608.1
Great Britain	Validation of EP patent	Dehmel & Bettenhausen Patentanwälte	17/09/07	<b>TBI-001GB</b>	Issued EP 2064229

Ireland	Validation of EP patent	Dehmel & Bettenhausen Patentanwälte	17/09/07	TBI-001IE	Issued EP 2064229
Italy	Validation of EP patent	Perani & Partners S.P.A.	17/09/07	TBI-001IT	Issued 502015000071945
Luxembourg	Validation of EP patent	Dehmel & Bettenhausen Patentanwälte	17/09/07	TBI-001LU	Issued EP 2064229
Netherlands	Validation of EP patent	Dehmel & Bettenhausen Patentanwälte	17/09/07	TBI-001NL	Issued EP 2064229
Spain	Validation of EP patent	Balder IP Law	17/09/07	TBI-001ES	Issued ES 2551892
Japan	2009527930	Shimizu Patent Office	17/09/07	TBI-001JP	Published
US	12/441,494	Morgan Lewis	17/09/07	TBI-001US	Issued 8,481,023
US	13/937,043	Morgan Lewis	08/07/13	TBI-001USDIV	Published

<b>Patent Family: TBI-003</b>					
<b>Inventors:</b> John Bell and Dave Stojdl			<b>Owners:</b> Ottawa Hospital Research Institute, and Children's Hospital of Eastern Ontario Research Institute Inc.		
<b>Patent Family:</b> Oncolytic Rhabdovirus  (Abstract – Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties <i>in vitro</i> and <i>in vivo</i> )					<b>Priority Date:</b> December 10, 2009 (US 61/285,461)
<b>Country</b>	<b>Number</b>	<b>Associate</b>	<b>Filing Date</b> dd/mm/yr	<b>Reference No.</b>	<b>Status or Patent No.</b>
PCT	PCT/IB10/003396 WO 11/070440 (published 16/06/11)  Originally identified as PCT/US2010/059903	BLG	10/12/10	TBI-003PC	National Phase In: Australia, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico and US
Australia	2010329551	Griffith Hack	10/12/10	TBI-003AU	Issued 2010329551

Australia	2016202789	Griffith Hack	10/12/10	<b>TBI-003AUDIV</b>	Pending
Brazil	BR 11 2012 013644-0	Magellan IP Propriedade Intelectual Ltda.	10/12/10	<b>TBI-003BR</b>	Pending
Canada	2,836,117	BLG	10/12/10	<b>TBI-003CA</b>	Pending
China	201080063490.X	WinGuan Patent and Trademark Attorneys	10/12/10	<b>TBI-003CN</b>	Issued 102585989
Europe	10835567.8	ABG Patentes, S.L.	10/12/10	<b>TBI-003EP</b>	Issued 2510088
Austria	Validation of European Patent	REDL Life Science Patent Attorneys	10/12/10	<b>TBI-003AT</b>	Issued AT E 834694
Belgium	Validation of EP patent	BIIP Business- Integrated Intellectual Property	10/12/10	<b>TBI-003BE</b>	Issued EP 2510088
France	Validation of EP patent	ICOSA European Patent Attorneys	10/12/10	<b>TBI-003FR</b>	Issued EP 2510088
Germany	Validation of EP patent	Gleiss & Große	10/12/10	<b>TBI-003DE</b>	Issued 60 2010 037 038.0
Ireland	Validation of EP patent	MacLachlan & Donaldson	10/12/10	<b>TBI-003IE</b>	Issued EP 2510088
Italy	Validation of EP patent	Jacobacci & Partners S.p.A.	10/12/10	<b>TBI-003IT</b>	Issued 502016000131903
Luxembourg	Validation of EP patent	Molitor	10/12/10	<b>TBI-003LU</b>	Issued EP 2510088
Netherland	Validation of EP patent	Vereenigde Octrooibureaux N.V.	10/12/10	<b>TBI-003NL</b>	Issued EP 2510088
Spain	Validation of EP patent	ABG Patentes, S.L.	10/12/10	<b>TBI-003ES</b>	Issued EP 2510088
United Kingdom	Validation of EP patent	HGF Limited	10/12/10	<b>TBI-003UK</b>	Issued EP 2510088
India	6009/DELNP/2012	Lakshmikumaran & Sridharan	10/12/10	<b>TBI-003IN</b>	Pending
Israel	220221	Ben-Ami & Associates	10/12/10	<b>TBI-003IL</b>	Published
Japan	2012-542635	Soei Patent & Law Firm	10/12/10	<b>TBI-003JP</b>	Published
Japan	2016-105211	Soei Patent & Law Firm	10/12/10	<b>TBI-003JP</b>	Pending



Mexico	MX/a/2012/006508	Panamericana de Patentes Y Marcas, S.C.	10/12/10	TBI-003MX	Issued 337062
Mexico	MX/a/2016/001812	Panamericana de Patentes Y Marcas, S.C.	10/12/10	TBI-003MX	Pending
United States	13/514,837	BLG	10/12/10	TBI-003US	Issued 9,045,729
United States	14/696,028	BLG	24/04/15	TBI-003USDIV	Published

<b>Patent Family: TBI-004</b>					
<b>Inventors:</b> Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay and John Bell			<b>Owners:</b> McMaster University, and Ottawa Hospital Research Institute		
<b>Patent Family:</b> A Method of Vaccination Comprising a Histone Deacetylase Inhibitor  (Abstract -- A vaccination method is provided. The method comprises administering to a mammal a histone deacetylase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity)					<b>Priority Date:</b> March 11, 2011 (US 61/451,794)
<b>Country</b>	<b>Number</b>	<b>Associate</b>	<b>Filing Date</b> dd/mm/yr	<b>Reference No.</b>	<b>Status or Patent No.</b>
PCT	PCT/CA12/000212  WO 12/122629 (published 20/09/12)	Gowlings	09/03/12	TBI-004PC	National Phase In: Canada, China, Europe, Japan and US
Canada	2,829,607	Gowlings	09/03/12	TBI-004CA	Pending
China	201280020513		09/03/12	TBI-004CN	Pending
Europe	2012757601	Sagittarius IP	09/03/12	TBI-004EP	Pending
Japan	2013556943	Okuyama & Sasajima	09/03/12	TBI-004JP	Pending
United States	14/004,546	Gowlings	09/03/12	TBI-004US	Pending

<b>Patent Family: TBI-005</b>					
<b>Inventors:</b> John Bell and Dave Stojdl			<b>Owners:</b> Ottawa Hospital Research Institute, and Children's Hospital of Eastern Ontario Research Institute Inc.		
<b>Patent Family:</b> Compositions and Methods for the Treatment of Brain Cancers  ( <b>Abstract</b> – Described herein is an isolated viral particle having a genome that includes open reading frames that encode: Maraba proteins N, P and L or variants thereof; as well as Maraba protein M or protein delta 51M, or variants thereof; and a Bahia Grande G protein, a LCMV G protein, or an Ebola G protein. Maraba protein N may have a sequence which includes SEQ ID NO:3. Maraba proteins M and delta 51M may have sequence which include SEQ ID NO: 4 and 5, respectively. Bahia Grande G protein may have a sequence which includes SEQ ID NO: 6. LCMV G protein may have a sequence which includes SEQ ID NO: 7. Ebola G protein may have a sequence which includes SEQ ID NO: 8)					<b>Priority Date:</b> None
Country	Number	Associate	Filing Date dd/mm/yr	Reference No.	Status or Patent No.
PCT	PCT/CA12/050893  WO 14/089668 (published 19/06/14)	BLG	12/12/12	TBI-005PC	National Phase Entry in: Australia, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, Russia and US
Australia	2012396787	Griffith Hack	12/12/12	TBI-005AU	Pending
Brazil	BR 11 2015 013669.9	Magellan IP Propriedade Intelectual Ltda.	12/12/12	TBI-005BR	Pending
Canada	2,894,618	BLG	12/12/12	TBI-005CA	Pending
China	201280077698.6	DEQI Intellectual Property Law Corporation	12/12/12	TBI-005CN	Published
Europe	12889818.6	ABG Patentés, S.L.	12/12/12	TBI-005EP	Published
India	5049/DELNP/2015	Lakshmikumaran & Sridharan	12/12/12	TBI-005IN	Published
Israel	239374	Ben-Ami & Associates	12/12/12	TBI-005IL	Published

Japan	2015-546782	Soei Patent & Law Firm	12/12/12	<b>TBI-005JP</b>	Published
Mexico	MX/a/2015/007093	Panamericana de Patentes Y Marcas, S.C.	12/12/12	<b>TBI-005MX</b>	Pending
Russia	2015128078	Sojuzpatent	12/12/12	<b>TBI-005RU</b>	Published
United States	14/651,761	BLG	12/12/12	<b>TBI-005US</b>	Published

<b>Patent Family: TBI-006</b>					
<b>Inventors:</b> Dave Stojdl, John Bell, Brian Lichty and Jonathan Pol			<b>Owners:</b> Ottawa Hospital Research Institute, Children's Hospital of Eastern Ontario Research Institute Inc., and McMaster University		
<b>Patent Family:</b> Vaccine Composition  ( <b>Abstract</b> – There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus)					<b>Priority Date:</b> February 21, 2013 (US 61/767,776)
<b>Country</b>	<b>Number</b>	<b>Associate</b>	<b>Filing Date</b> dd/mm/yr	<b>Reference No.</b>	<b>Status or Patent No.</b>
PCT	PCT/CA14/050118  WO 14/127478 (published 28/08/14)	BLG	20/02/14	<b>TBI-006PC</b>	National Phase Entry in: Australia, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, Russia and US
Australia	2014221143	Griffith Hack	20/02/14	<b>TBI-006AU</b>	Pending
Brazil	BR 11 2015 019838.4	Magellan IP Propriedade Intelectual Ltda.	20/02/14	<b>TBI-006BR</b>	Pending
Canada	2,901,501	BLG	20/02/14	<b>TBI-006CA</b>	Pending

China	201480020723.6	DEQI Intellectual Property Law Corporation	20/02/14	<b>TBI-006CN</b>	Pending
Europe	14754562.8	ABG Patentes, S.L.	20/02/14	<b>TBI-006EP</b>	Published
India	7820/DELNP/2015	Lakshmikumaran & Sridharan	20/02/14	<b>TBI-006IN</b>	Pending
Israel	240723	Ben-Ami & Associates	20/02/14	<b>TBI-006IL</b>	Published
Japan	2015-558314	Soei Patent & Law Firm	20/02/14	<b>TBI-006JP</b>	Published
Mexico	MX/a/2015/010783	Panamericana de Patentes Y Marcas, S.C.	20/02/14	<b>TBI-006MX</b>	Pending
Russia	2015135890	Patentica	20/02/14	<b>TBI-006RU</b>	Pending
United States	14/769,035	BLG	20/02/14	<b>TBI-006US</b>	Published

<b>Patent Family: TBI-007</b>					
<b>Inventors:</b> John Bell and Fabrice LeBoeuf			<b>Owner:</b> Ottawa Hospital Research Institute		
<b>Patent Family:</b> Engineered Synergistic Oncolytic Viral Symbiosis  <b>(Abstract –</b> In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host.)					<b>Priority Date:</b> August 21, 2008 (US 61/767,776)
Country	Number	Associate	Filing Date dd/mm/yr	Reference No.	Status or Patent No.
PCT	PCT/CA09/001176  WO 10/020056 (published 24/02/10)	Smart & Biggar	20/08/09	TBI-007PC	National Phase in Canada, Europe, Japan and US
Canada	2,734,740	Gowlings	20/08/09	TBI-007CA	Pending
Europe	2009807799	Dehmel & Bettenhausen Patentwälte PartmbB	20/08/09	TBI-007EP	Published
Japan	2011523281	Hiraki & Associates	20/08/09	TBI-007JP	Abandoned
United States	13/060,028	Morgan Lewis & Bockius LLP	20/08/09	TBI-007US	Published

<b>Patent Family: TBI-008</b>					
<b>Inventors:</b> John Bell, Fabrice LeBoeuf and Jean-Simon Diallo			<b>Owner:</b> Ottawa Hospital Research Institute		
<b>Patent Family:</b> Recombinant Oncolytic Virus Expressing an IFN Binding Protein  (Abstract –The present disclosure provides a recombinant interferon (IFN)-sensitive oncolytic rhabdovirus that includes a polynucleotide sequence encoding a soluble protein that binds IFN- $\alpha$ , IFN- $\beta$ , or both. The soluble protein is referred to herein as an “interferon binding protein”. The interferon binding protein is secretable by a cell infected with the oncolytic rhabdovirus)					<b>Priority Date:</b> June 7, 2013 (US 61/832,740)
Country	Number	Associate	Filing Date dd/mm/yr	Reference No.	Status or Patent No.
PCT	PCT/CA14/050534  WO 14/194433 (published 11/12/14)	BLG	09/06/14	TBI-008PC	National Phase Entry deadline 07/12/15

<b>Patent Family: TBI-009</b>					
<b>Inventors:</b> Carolina Ilkow, Fabrice LeBoeuf, John Bell, Jean-Simon Diallo and Rozanne Arulanandam			<b>Owner:</b> Ottawa Hospital Research Institute		
<b>Patent Family:</b> Compositions and Methods for Enhancing Virus Replication  (Abstract – Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.)					<b>Priority Date:</b> June 14, 2013 (US 61/835,446)
Country	Number	Associate	Filing Date dd/mm/yr	Reference No.	Status or Patent No.
PCT	PCT/CA14/050564  WO 14/198003 (published 18/12/14)	BLG	16/06/14	TBI-009PC	National Phase in Canada, Europe, and US
Canada	2,915,045	BLG	16/06/14	TBI-009CA	Pending
Europe	14811047.1	ABG Patentes, S.L.	16/06/14	TBI-009EP	Published
United States	14/898,083	BLG	16/06/14	TBI-009US	Published

<b>Patent Family: TBI-010</b>					
<b>Inventors:</b> John Bell, Fabrice Le Boeuf, Mark Tangney and Michelle Cronin			<b>Owners:</b> Ottawa Hospital Research Institute, and University College Cork		
<b>Patent Family:</b> A Bacterium Producing an Interferon Binding Protein and Uses Thereof  (Abstract – Described herein is a non-invasive bacterium that includes a polynucleotide sequence encoding a soluble interferon binding protein that binds IFN- $\alpha$ , IFN- $\beta$ or both, wherein the soluble protein is secretable by the bacterium. The bacterium may be used to aid in the replication of an IFN-sensitive oncolytic virus in a tumorous cancer in a patient.)					<b>Priority Date:</b> June 14, 2013 (US 61/835,453)
Country	Number	Associate	Filing Date dd/mm/yr	Reference No.	Status or Patent No.
PCT	PCT/CA14/050563  WO 14/198002 (published 18/12/14)	BLG	16/06/14	TBI-010PC	National Phase Entry deadline 07/12/15